Uric acid rises often in people with metabolic syndrome, insulin resistance, and chronic kidney disease. Elevated levels can trigger gout or kidney stones. Many clinicians also wonder whether high uric acid accelerates kidney decline. This study helps clarify that question.
Researchers followed 3,885 adults with chronic kidney disease stages 2 through 4. All participants were part of the CRIC study, a long-running national cohort designed to track the metabolic and cardiovascular complications of kidney disease. Investigators measured baseline uric acid levels and then monitored kidney outcomes and survival for almost eight years.
During follow-up, 885 people reached kidney failure that required dialysis or transplant. Another 789 participants died. The researchers used statistical models that adjusted for age, sex, blood pressure, diabetes, proteinuria, medications, and baseline kidney function. This approach helped isolate the role of uric acid from other common CKD risks.
Higher uric acid showed a clear relationship with kidney outcomes, but only in the earlier stages of disease. Adults with an estimated GFR of at least 45 milliliters per minute (CKD stage 3a) had a significant increase in kidney failure risk for every standard-deviation rise in uric acid. The hazard ratio reached 1.40, which suggests a meaningful effect. In patients with eGFR 30 to 44 (stage 3b), the association weakened and lost statistical significance. In stage 4 CKD, the link disappeared entirely.
These patterns suggest that uric acid may play a larger role when kidney tissue still holds enough reserve to respond to inflammation or oxidative stress. Once kidney function drops below 30 milliliters per minute, structural injury may dominate the progression process, and uric acid may matter less.
The study also uncovered a J-shaped curve for mortality. Very high uric acid increased the risk of death, but very low levels did as well. This pattern echoes findings from cardiovascular and metabolic literature, where extremes sometimes signal underlying illness or malnutrition.
The authors note important limitations. The study was observational, so it cannot prove that uric acid directly causes kidney decline. Also, researchers did not track changes in uric acid over time. Despite these limitations, the results strengthen the case for clinical trials that test whether lowering uric acid in earlier CKD stages can slow disease progression.
Future interventional studies will clarify whether high uric acid is just a marker or a modifiable risk factor.
References:
- Srivastava A, Kaze AD, McMullan CJ, et al. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018;71(3):362-370. doi:10.1053/j.ajkd.2017.08.017.
About Dr. Gerti Tashko, MD
Dr. Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland. He is uniquely quadruple board-certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice delivers root-cause-focused metabolic and endocrine care, available virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to improve long-term health.
